BCL2L1 and Thrombocytopenia: The inhibition of BCL-XL with an inhibitor, however, induces severe thrombocytopenia, an on-target and dose-limiting toxicity, which limits the use of ABT263 and other BCL-XL inhibitors as safe and effective anticancer drugs in clinic14,15.